Referências
Principais artigos
Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Texto completo Resumo
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2024 [internet publication].Texto completo
Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Resumo
Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Resumo
Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Texto completo
Artigos de referência
1. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007 Sep;7(9):581-96. Resumo
2. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov;5(11):873-82. Resumo
3. Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol. 1999 May-Jun;17(3):279-89. Resumo
4. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev. 2001 Oct;14(4):659-88.Texto completo Resumo
5. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008 Mar;8(3):191-9. Resumo
6. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003 Feb;3(2):87-98. Resumo
7. World Health Organization. The post kala-azar dermal leishmaniasis (PKDL) atlas: a manual for health workers. 2012 [internet publication].Texto completo
8. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Texto completo Resumo
9. Cabello I, Caraballo A, Millan Y. Leishmaniasis in the genital area. Rev Inst Med Trop Sao Paulo. 2002 Mar-Apr;44(2):105-7.Texto completo Resumo
10. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000Res. 2017 May 26;6:750.Texto completo Resumo
11. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol. 2003 Oct;97 Suppl 1:107-14. Resumo
12. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-76. Resumo
13. Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop. 2008 Jan;105(1):1-9. Resumo
14. World Health Organization. Fact sheet: leishmaniasis. Jan 2023 [internet publication].Texto completo
15. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2024 [internet publication].Texto completo
16. World Health Organization. Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map. 2024 [internet publication].Texto completo
17. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008 Apr;21(2):334-59.Texto completo Resumo
18. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006 Jan;19(1):111-26.Texto completo Resumo
19. Wright NA, Davis LE, Aftergut KS, et al. Cutaneous leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008 Apr;58(4):650-2. Resumo
20. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004 Feb;53(2):158-66.Texto completo Resumo
21. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM. 2004 Dec;97(12):781-8. Resumo
22. Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004 Dec 1;39(11):1674-80.Texto completo Resumo
23. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.Texto completo Resumo
24. Myles O, Wortmann GW, Cummings JF, et al. Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med. 2007 Sep 24;167(17):1899-901. Resumo
25. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002 Aug 1;35(3):261-7.Texto completo Resumo
26. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and reserve components, U.S. Armed Forces, 2001-2016. MSMR. 2017 Feb;24(2):2-7. Resumo
27. Mody RM, Lakhal-Naouar I, Sherwood JE, et al. Asymptomatic visceral Leishmania infantum infection in US soldiers deployed to Iraq. Clin Infect Dis. 2019 May 30;68(12):2036-44.Texto completo Resumo
28. Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg Infect Dis. 2006 Mar;12(3):440-6.Texto completo Resumo
29. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006 Dec;22(12):552-7. Resumo
30. World Health Organization. Bangladesh achieves historic milestone by eliminating kala-azar as a public health problem. 2023 [internet publication].Texto completo
31. Sereno D. Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens. New Microbes New Infect. 2019 Apr 4;30:100540.Texto completo Resumo
32. Leelayoova S, Siripattanapipong S, Manomat J, et al. Leishmaniasis in Thailand: a review of causative agents and situations. Am J Trop Med Hyg. 2017 Mar;96(3):534-42.Texto completo Resumo
33. Desbois N, Pratlong F, Quist D, et al. Leishmania (Leishmania) martiniquensis n. sp. (Kinetoplastida: Trypanosomatidae), description of the parasite responsible for cutaneous leishmaniasis in Martinique Island (French West Indies). Parasite. 2014;21:12.Texto completo Resumo
34. Depaquit J, Kaltenbach ML, Gay F. Visceral leishmaniasis in traveler to Guyana caused by Leishmania siamensis, London, UK. Emerg Infect Dis. 2018 Aug;24(8):1599-600.Texto completo Resumo
35. Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol. 2005;59:1-75. Resumo
36. Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun. 2002 Dec;70(12):6919-25.Texto completo Resumo
37. Weirather JL, Duggal P, Nascimento EL, et al. Comprehensive candidate gene analysis for symptomatic or asymptomatic outcomes of Leishmania infantum infection in Brazil. Ann Hum Genet. 2017 Jan;81(1):41-8.Texto completo Resumo
38. Rogers ME, Ilg T, Nikolaev AV, et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature. 2004 Jul 22;430(6998):463-7. Resumo
39. Vannier-Santos MA, Martiny A, de Souza W. Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des. 2002;8(4):297-318. Resumo
40. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000 Nov;2(14):1765-73. Resumo
41. Belkaid Y, Valenzuela JG, Kamhawi S, et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly? Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6704-9.Texto completo Resumo
42. Warburg A, Saraiva E, Lanzaro GC, et al. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Philos Trans R Soc Lond B Biol Sci. 1994 Jul 29;345(1312):223-30. Resumo
43. Basu MK, Ray M. Macrophage and Leishmania: an unacceptable coexistence. Crit Rev Microbiol. 2005;31(3):145-54. Resumo
44. Kariyawasam KKGDUL, Selvapandiyan A, Siriwardana HVYD, et al. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies. Parasitology. 2018 Apr;145(4):443-52.Texto completo Resumo
45. Zhang WW, Ramasamy G, McCall LI, et al. Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog. 2014 Jul;10(7):e1004244.Texto completo Resumo
46. Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis. 1987 Dec;156(6):1030-3. Resumo
47. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 1999 Aug;13(8):459-65. Resumo
48. Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005 May;11(5):655-62.Texto completo Resumo
49. Brooker S, Mohammed N, Adil K, et al. Leishmaniasis in refugee and local Pakistani populations. Emerg Infect Dis. 2004 Sep;10(9):1681-4.Texto completo Resumo
50. Kolaczinski JH, Reithinger R, Worku DT, et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008 Apr;37(2):344-52. Resumo
51. Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):184-8.Texto completo Resumo
52. Pennisi MG, Cardoso L, Baneth G, et al. LeishVet update and recommendations on feline leishmaniosis. Parasit Vectors. 2015 Jun 4;8:302.Texto completo Resumo
53. Asfaram S, Fakhar M, Teshnizi SH. Is the cat an important reservoir host for visceral leishmaniasis? A systematic review with meta-analysis. J Venom Anim Toxins Incl Trop Dis. 2019 Jun 10;25:e20190012.Texto completo Resumo
54. Public Health England. HAIRS risk assessment: canine leishmaniosis. Jan 2022 [internet publication].Texto completo
55. World Veterinary Association. WVA policies: WVA position statement on Leishmaniosis. Apr 2021 [internet publication].Texto completo
56. Kopterides P, Mourtzoukou EG, Skopelitis E, et al. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1181-9. Resumo
57. Català A, Roé E, Dalmau J, et al. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015;230(3):204-7.Texto completo Resumo
58. Arens K, Filippis C, Kleinfelder H, et al. Anti-tumor necrosis factor α therapeutics differentially affect Leishmania infection of human macrophages. Front Immunol. 2018 Jul 31;9:1772.Texto completo Resumo
59. World Health Organization. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. June 2022 [internet publication].Texto completo
60. Stockdale L, Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis. 2013 Jun 20;7(6):e2278.Texto completo Resumo
61. Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011 Apr;11(4):322-5. Resumo
62. Romero GA, Boelaert M. Control of visceral leishmaniasis in Latin America: a systematic review. PLoS Negl Trop Dis. 2010 Jan 19;4(1):e584.Texto completo Resumo
63. González U, Pinart M, Sinclair D, et al, Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev. 2015 Aug 5;2015(8):CD008736.Texto completo Resumo
64. Picado A, Singh SP, Rijal S, et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ. 2010 Dec 29;341:c6760.Texto completo Resumo
65. Chowdhury R, Dotson E, Blackstock AJ, et al. Comparison of insecticide-treated nets and indoor residual spraying to control the vector of visceral leishmaniasis in Mymensingh District, Bangladesh. Am J Trop Med Hyg. 2011 May;84(5):662-7. Resumo
66. Costa CH. How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):232-42.Texto completo Resumo
67. Sousa-Paula LC, Silva LGD, Sales KGDS, et al. Failure of the dog culling strategy in controlling human visceral leishmaniasis in Brazil: a screening coverage issue? PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0007553.Texto completo Resumo
68. Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis. 1991 Sep-Oct;13(5):1009-17. Resumo
69. Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis. 2017 May 12;11(5):e0005527.Texto completo Resumo
70. ClinicalTrials.gov. A study to assess the safety, efficacy and immunogenicity of leishmania vaccine ChAd63-KH in PKDL. May 2023 [internet publication].Texto completo
71. ClinicalTrials.gov. A study of a new leishmania vaccine candidate ChAd63-KH (Leish2a). Jan 2020 [internet publication].Texto completo
72. Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021 Jul 7;29(7):2366-77.Texto completo Resumo
73. Boelaert M, Bhattacharya S, Chappuis F, et al. Evaluation of rapid diagnostic tests: visceral leishmaniasis. Nat Rev Microbiol. 2007;5(suppl):S30-9.
74. Escobar MA, Martinez F, Scott Smith D, et al. American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop Doct. 1992;22 Suppl 1:69-78;63-4. Resumo
75. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007 Jan;45(1):21-5.Texto completo Resumo
76. Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Resumo
77. Sevilha-Santos L, Dos Santos Júnior ACM, Medeiros-Silva V, et al. Accuracy of qPCR for quantifying Leishmania kDNA in different skin layers of patients with American tegumentary leishmaniasis. Clin Microbiol Infect. 2019 Feb;25(2):242-7.Texto completo Resumo
78. Cota GF, de Sousa MR, Demarqui FN, et al. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012;6(5):e1665.Texto completo Resumo
79. Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol. 2006 Jul;44(7):2343-7.Texto completo Resumo
80. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):673-5. Resumo
81. De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg. 2006 Oct;75(4):739-43.Texto completo Resumo
82. Boelaert M, Rijal S, Regmi S, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg. 2004 Jan;70(1):72-7.Texto completo Resumo
83. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis. 2000 Oct;31(4):1093-5.Texto completo Resumo
84. Weigle KA, de Dávalos M, Heredia P, et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg. 1987 May;36(3):489-96. Resumo
85. Kager PA, Rees PH. Splenic aspiration. Review of the literature. Trop Geogr Med. 1983 Jun;35(2):111-24. Resumo
86. Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):505-7. Resumo
87. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005 Jun;72(6):811-4. Resumo
88. Schuster FL, Sullivan JJ. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev. 2002 Jul;15(3):374-89.Texto completo Resumo
89. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002 Sep;9(5):951-8.Texto completo Resumo
90. Maurya R, Singh RK, Kumar B, et al. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. J Clin Microbiol. 2005 Jul;43(7):3038-41.Texto completo Resumo
91. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ. 2006 Oct 7;333(7571):723.Texto completo Resumo
92. Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev. 2014 Jun 20;2014(6):CD009135.Texto completo Resumo
93. Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):32-40. Resumo
94. de Assis TS, Braga AS, Pedras MJ, et al. Multi-centric prospective evaluation of rk39 rapid test and direct agglutination test for the diagnosis of visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2011 Feb;105(2):81-5. Resumo
95. Harith AE, Kolk AH, Kager PA, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg. 1987;81(4):603-6. Resumo
96. Iqbal J, Hira PR, Saroj G, et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol. 2002 Feb;40(2):475-9.Texto completo Resumo
97. Marty P, Lelièvre A, Quaranta JF, et al. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):690-1. Resumo
98. Singh RK. Hyperreactive malarial splenomegaly in expatriates. Travel Med Infect Dis. 2007 Jan;5(1):24-9. Resumo
99. Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006 Sep 23;368(9541):1106-18. Resumo
100. Schaefer KU, Kurtzhals JA, Gachihi GS, et al. A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):471-5. Resumo
101. Davies CR, Llanos-Cuentas EA, Pyke SD, et al. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect. 1995 Apr;114(2):297-318.Texto completo Resumo
102. Cardo LJ. Leishmania: risk to the blood supply. Transfusion. 2006 Sep;46(9):1641-5. Resumo
103. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. Resumo
104. Martínez-Valencia AJ, Daza-Rivera CF, Rosales-Chilama M, et al. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005713.Texto completo Resumo
105. Dereure J, Duong Thanh H, Lavabre-Bertrand T, et al. Visceral leishmaniasis: persistence of parasites in lymph nodes after clinical cure. J Infect. 2003 Jul;47(1):77-81. Resumo
106. Berman JD. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999 Jan;28(1):49-51.Texto completo Resumo
107. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 998;76(1):25-32.Texto completo Resumo
108. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006 Oct 1;43(7):917-24.Texto completo Resumo
109. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005 Dec;5(12):763-74. Resumo
110. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004 Feb 1;38(3):377-83.Texto completo Resumo
111. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000 Feb;13(4):243-8. Resumo
112. Carnielli JBT, Crouch K, Forrester S, et al. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. EBioMedicine. 2018 Oct;36:83-91.Texto completo Resumo
113. Tiwary P, Kumar D, Sundar S. Identification and functional validation of a biomarker for the diagnosis of miltefosine relapse during visceral leishmaniasis. Am J Trop Med Hyg. 2018 Feb;98(2):492-6.Texto completo Resumo
114. Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother. 2006 Oct;58(4):811-5.Texto completo Resumo
115. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother. 2005 Feb;55(2):229-33.Texto completo Resumo
116. Pekelharing JE, Gatluak F, Harrison T, et al. Outcomes of visceral leishmaniasis in pregnancy: a retrospective cohort study from South Sudan. PLoS Negl Trop Dis. 2020 Jan;14(1):e0007992.Texto completo Resumo
117. Sundar S, Chakravarty J. Antimony toxicity. Int J Environ Res Public Health. 2010 Dec;7(12):4267-77.Texto completo Resumo
118. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 2001 Nov;6(11):849-54.Texto completo Resumo
119. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8(4):319-42. Resumo
120. Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007 Aug;77(2):266-74. Resumo
121. Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011 May;118(2):87-96. Resumo
122. Heras-Mosteiro J, Monge-Maillo B, Pinart M, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067.Texto completo Resumo
123. Pinart M, Rueda JR, Romero GA, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD004834.Texto completo Resumo
124. Morizot G, Kendjo E, Mouri O, et al. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis. 2013 Aug;57(3):370-80.Texto completo Resumo
125. López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, et al. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016 Jul 26;16:360.Texto completo Resumo
126. Cardona-Arias JA, Vélez ID, López-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. 2015 May 26;10(5):e0122569.Texto completo Resumo
127. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. Resumo
128. Sosa N, Pascale JM, Jiménez AI, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019 May 2;13(5):e0007253.Texto completo Resumo
129. Soto J, Soto P, Ajata A, et al. Topical 15% paromomycin-aquaphilic for Bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clin Infect Dis. 2019 Feb 15;68(5):844-9.Texto completo Resumo
130. Kim DH, Chung HJ, Bleys J, et al. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3(2):e381.Texto completo Resumo
131. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One. 2017 Sep 19;12(9):e0184777.Texto completo Resumo
132. Soto J, Paz D, Rivero D, et al. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2016 Apr;94(4):852-6.Texto completo Resumo
133. Galvão EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS One. 2017 Oct 9;12(10):e0186117.Texto completo Resumo
134. Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Resumo
135. Roussel M, Nacher M, Frémont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006 Jun;100(4):307-14. Resumo
136. Lai A Fat EJ, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol. 2002 Nov;41(11):796-800. Resumo
137. Christen JR, Bourreau E, Demar M, et al. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Med Infect Dis. 2018 Jul - Aug;24:31-6. Resumo
138. Soto J, Soto P, Ajata A, et al. Miltefosine combined with intralesional pentamidine for Leishmania braziliensis cutaneous leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018 Nov;99(5):1153-5.Texto completo Resumo
139. Dorlo TP, Kager PA. Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis. 2008 May 28;2(5):e225.Texto completo Resumo
140. Machado PR, Rosa ME, Guimarães LH, et al. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clin Infect Dis. 2015 Sep 15;61(6):945-9.Texto completo Resumo
141. Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Texto completo
142. Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007 Aug;46(8):848-52. Resumo
143. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis. 2007 Aug 15;45(4):478-82.Texto completo Resumo
144. Avila-García M, Mancilla-Ramírez J, Segura-Cervantes E, et al. Transplacental transmission of cutaneous Leishmania mexicana strain in BALB/c mice. Am J Trop Med Hyg. 2013 Aug;89(2):354-8.Texto completo Resumo
145. Pan American Health Organization. Manual of procedures for leishmaniases surveillance and control in the Americas. Dec 2019 [internet publication].Texto completo
146. Cunha MA, Leão AC, de Cassia Soler R, et al. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the New World: a retrospective study. Am J Trop Med Hyg. 2015 Dec;93(6):1214-8.Texto completo Resumo
147. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007 Feb 1;44(3):350-6.Texto completo Resumo
148. Bansal N, Jain A. Managing visceral leishmaniasis. BMJ. 2023 Oct 16;383:2213.
149. Osman OF, Oskam L, Zijlstra EE, et al. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment. Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):397-400. Resumo
150. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11;362(6):504-12.Texto completo Resumo
151. Lucero E, Collin SM, Gomes S, et al. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis. 2015 Apr 2;9(4):e0003699.Texto completo Resumo
152. Goswami RP, Goswami RP, Das S, et al. Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome™). Am J Trop Med Hyg. 2016 Jan;94(1):93-8.Texto completo Resumo
153. Pandey K, Pal B, Siddiqui NA, et al. Efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India. Am J Trop Med Hyg. 2017 Nov;97(5):1498-502.Texto completo Resumo
154. Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635.Texto completo Resumo
155. Goyal V, Mahajan R, Pandey K, et al. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl Trop Dis. 2018 Oct 22;12(10):e0006830.Texto completo Resumo
156. Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis. 2015 Oct;28(5):426-37. Resumo
157. Gebreyohannes EA, Bhagvathula AS, Abegaz TM, et al. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018 Oct 19;7(1):108.Texto completo Resumo
158. Romero GAS, Costa DL, Costa CHN, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005706.Texto completo Resumo
159. Assis TSM, Rabello A, Cota G, et al. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180272.Texto completo Resumo
160. Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance programme. Clin Drug Investig. 2017 Mar;37(3):259-72.Texto completo Resumo
161. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011 Feb 5;377(9764):477-86. Resumo
162. Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21;356(25):2571-81.Texto completo Resumo
163. Jamil KM, Haque R, Rahman R, et al. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118.Texto completo Resumo
164. Akuffo H, Costa C, van Griensven J, et al. New insights into leishmaniasis in the immunosuppressed. PLoS Negl Trop Dis. 2018 May 10;12(5):e0006375.Texto completo Resumo
165. Gajurel K, Dhakal R, Deresinski S. Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients. Clin Transplant. 2017 Jan;31(1). Resumo
166. World Health Organization. WHO technical report series 949: control of the leishmaniases - report of a meeting of the WHO Expert Committee on the control of leishmaniases. 2010 [internet publication].Texto completo
167. Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988.Texto completo Resumo
168. Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-Miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-Arm, phase 3 trial. Clin Infect Dis. 2022 Oct 12;75(8):1423-32.Texto completo Resumo
169. Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013 May 2;7(5):e2195.Texto completo Resumo
170. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS. 1999 Jun 18;13(9):1063-9. Resumo
171. Delgado J, Macías J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999 Nov;61(5):766-9. Resumo
172. Diro E, Edwards T, Ritmeijer K, et al. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. PLoS Negl Trop Dis. 2019 Feb 21;13(2):e0007132.Texto completo Resumo
173. Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018 Jan 18;66(3):444-51.Texto completo Resumo
174. Clemente W, Vidal E, Girão E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015 Jan;21(1):89-95.Texto completo Resumo
175. Pijpers J, den Boer ML, Essink DR, et al. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - a review and meta-analysis. PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007173.Texto completo Resumo
176. World Health Organization. Statement on miltefosine - potential ocular disorders in patients treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL). Feb 2022 [internet publication].Texto completo
177. Basher A, Maruf S, Nath P, et al. Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh – a series of four cases. Am J Trop Med Hyg. 2017 Oct;97(4):1111-5.Texto completo Resumo
178. Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005 Sep;99(6):563-9. Resumo
179. Moulik S, Chaudhuri SJ, Sardar B, et al. Monitoring of parasite kinetics in Indian post-kala-azar dermal leishmaniasis. Clin Infect Dis. 2018 Jan 18;66(3):404-10.Texto completo Resumo
180. Ramesh V, Dixit KK, Sharma N, et al. Assessing the efficacy and safety of liposomal amphotericin B and miltefosine in combination for treatment of post kala-azar dermal leishmaniasis. J Infect Dis. 2020 Feb 3;221(4):608-17.Texto completo Resumo
181. Centers for Disease Control and Prevention. Leishmaniasis: clinical care of leishmaniasis. Mar 2024 [internet publication].Texto completo
182. World Health Organization. WHO technical report series 949: control of the leishmaniases – report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. 2010 [internet publication].Texto completo
183. World Health Organization. South Sudan intensifies measures against visceral leishmaniasis to improve health and social well-being of affected populations. Nov 2018 [internet publication].Texto completo
184. Drugs for Neglected Diseases initiative. Fexinidazole/miltefosine combination (VL). Aug 2016 [internet publication].Texto completo
185. Drugs for Neglected Diseases Initiative. DNDI-0690. Aug 2019 [internet publication].Texto completo
186. ClinicalTrials.gov. Single oral dose escalation study of DNDI-0690 in healthy male subjects. Dec 2022 [internet publication].Texto completo
187. Drugs for Neglected Diseases initiative. R&D portfolio update February 2019: DNDi Leishmaniasis programme. Feb 2019 [internet publication].Texto completo
188. ClinicalTrials.gov. Safety, tolerability and pharmacokinetics (PKs) investigation of GSK3186899 in healthy subjects. Feb 2023 [internet publication].Texto completo
189. Alves F, Bilbe G, Blesson S, et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018 Oct;31(4):.Texto completo Resumo
190. Drugs for Neglected Diseases initiatives. Annual report 2020: medicines for the people. 2020 [internet publication].Texto completo
191. World Health Organization. Promising patient-friendly oral drug against visceral leishmaniasis enters phase II clinical trial in Ethiopia. 2024 [internet publication].Texto completo
192. Hossain MS, Kumar A, Hossain AFMA, et al. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infect Dis Poverty. 2018 Aug 13;7(1):80.Texto completo Resumo
193. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006 Aug 1;43(3):357-64.Texto completo Resumo
194. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004 Mar 1;38(5):612-9.Texto completo Resumo
195. Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol. 2008 Jan;102(1):11-9.Texto completo Resumo
196. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011 Jun;5(6):e1153.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal